Cognetivity Neurosciences Ltd. announced that it has signed a distribution agreement with Dubai-based medical technology company Emitac Healthcare Solutions ("Emitac"). Under the terms of the agreement, Emitac has become an official distributor of CognICA™, Cognetivity's medical device product, in the Middle East region. CognICA is FDA-registered and CE-marked, and has already been commercially deployed across three continents, including within the UK's National Health Service (NHS) and in the Clemenceau Medical Center in Dubai.

The new agreement grants Cognetivity access to Emitac's wealth of experience and connections in the Middle East, as well as the full range of its customer support services, in order to bolster CognICA's already-impressive commercial rollout in the region. News of the partnership coincides with the appearance of both companies at Arab Health 2022. Taking place in Dubai from 24 to 27 January, Arab Health is the medical equipment exhibition in the Middle East, with exhibitors from over 60 countries participating and more than 56,000 healthcare professionals due to attend.

Cognetivity's attendance at Arab Health and the burgeoning commercial rollout of CognICA across the Middle East come at a salient moment for the region. According to a study published this year in The Lancet Public Health, the UAE and other Gulf countries will experience the highest increases worldwide in the number of people living with dementia by 2050. This represents a major impending healthcare challenge, which cutting-edge technology such as Cognetivity's will play a vital part in tackling.